NOBILIS REO 1133 FREEZE DRIED PELLET WITH ACCOMPANYING SUSPENDING LIQUID Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

nobilis reo 1133 freeze dried pellet with accompanying suspending liquid

intervet international bv (0000000669) wim de korvestraat 35, boxmeer, nl-5831 - live reo virus, strain 1133 - freeze dried pellet with accompanying suspending liquid - live reo virus, strain 1133 (8000000825) 0tcid50

POLIOMYELITIS VACCINE SUSPENSION FOR INJECTION Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

poliomyelitis vaccine suspension for injection

bilthoven biologicals b.v. (0000012092) antonie van leeuwenhoeklaan 9-13, ma bilthoven, 3721 - inactivated poliomyelitis vaccine type 1(mahoney); inactivated poliomyelitis vaccine type 2(mef-1); inactivated poliomyelitis vaccine type 3(saukett) - suspension for injection - inactivated poliomyelitis vaccine type 1(mahoney) (8000003623) 40u; inactivated poliomyelitis vaccine type 2(mef-1) (8000003624) 8u; inactivated poliomyelitis vaccine type 3(saukett) (8000003626) 32u

CAA VACCINE NOBILIS Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

caa vaccine nobilis

intervet international bv (0000000669) wim de korvestraat 35, boxmeer, nl-5831 - chicken anaemia virus, strain 26p4 - chicken anaemia virus, strain 26p4 (8900000005) 0tcid50 - chicken anaemia

Vectormune FP ILT + AE Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

vectormune fp ilt + ae

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - Κοτόπουλο - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

DRIED FACTOR VIII, 8Y 250IU POWDER FOR SOLUTION FOR INJECTION Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

dried factor viii, 8y 250iu powder for solution for injection

bio products laboratory limited (0000009242) dagger lane, elstree, hertfordshire, wd6 3bx - factor viii (antihaemofilic factor) - powder for solution for injection - 250iu - factor viii (antihaemofilic factor) (0009001278) 250iu - coagulation factor viii

MENINGOCOCCAL POLYSACCHARIDE VACCINE A+C Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

meningococcal polysaccharide vaccine a+c

sanofi pasteur. - neisseria meningitidis a,ΠΟΛΥΣΑΚΧΑΡΊΤΗ, ΜΗΝΙΓΓΙΤΙΔΌΚΟΚΚΟΣ c,ΠΟΛΥΣΑΚΧΑΡΊΤΗ - powder & solvent for suspension for injection - 100mcg - 8000000697 - neisseria meningitidis a,polysaccharide - 50 ug; 8000000698 - neisseria meningitidis c,polysaccharide - 50 ug - meningococcus, bivalent purified polysacc. antigen

PG 600 POWDER & SOLVENT FOR SOLUTION FOR INJECTION Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

pg 600 powder & solvent for solution for injection

intervet international bv (0000000669) wim de korvestraat 35, boxmeer, nl-5831 - chorionic gonadotrophin; serum gonadotrophin - powder & solvent for solution for injection - chorionic gonadotrophin (0009002613) 200iu; serum gonadotrophin (0009002704) 420iu - gonadotrophins, combinations

Suvaxyn CSF Marker Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

suvaxyn csf marker

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - Χοίροι - Για την ενεργή ανοσοποίηση των χοίρων από την ηλικία των 7 εβδομάδων έως την πρόληψη της θνησιμότητας και τη μείωση της μόλυνσης και της νόσου που προκαλείται από τον ιό της κλασικής πανώλους των χοίρων (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.